p #60; 0.001. Data from [74]. Center for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA ...
Everyday Health on MSN
How to ease ulcerative colitis symptoms during a flare
Ease the symptoms of a UC flare, such as diarrhea, abdominal pain, and fever using expert-backed tips, and learn when to seek ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
A national audit of total abdominal colectomy for ulcerative colitis finds low 30 day mortality and a rise in laparoscopic ...
Although acute severe ulcerative colitis (ASUC) is recognized as a life-threatening flare associated with elevated thrombotic risk, the extent and duration of hypercoagulability after hospital ...
Upadacitinib shows sustained efficacy in UC, with over half maintaining clinical remission through 144 weeks in a phase 3 LTE study. Real-world data from the IBD-DACH study confirmed upadacitinib's ...
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon driven by an abnormal immune response. It typically begins in the rectum and spreads continuously, occasionally involving a cecal ...
Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...
Researchers have identified a gut-genetic interaction that could trigger an overactive immune response in the colon — offering one possible explanation for the pain and bleeding of ulcerative colitis, ...
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...
Northwestern Medicine investigators have identified a surprising culprit in the progression of inflammatory bowel disease: a naturally occurring metabolic compound in the gut, according to a study ...
Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo Itolizumab achieved key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback